Microbot Medical, Inc. Common Stock
Here’s whether Microbot Medical, Inc. Common Stock (MBOT) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 40 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.05% over 10 days); weak 1-year return of -50.5%; 3-month momentum negative (-16.2%); rising volume on a downtrend (distribution, 1.35x avg). Currently 66.8% off its 52-week high. Score: -5/7.
MBOT is trading below its 200-day MA ($2.08) — a key warning sign the longer-term trend is under pressure. An RSI of 40.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -50.5% compares to +20.4% for SPY (trailed the market by 70.8%). The current 66.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.